5.0 PATIENT ELIGIBILITY (See Section 1.0) 
5.1 All patients enrolled on the MISMUD protocol will be eligible for this 
protocol. 
5.1.1 Patients with ALL or high grade (Stage III or IV) T cell non-Hodgkin 
lymphoma who obtain a clinical remission after having relapsed during 
or after treatment with intensive multiagent chemotherapy. 
5.1.2 Patients with a proven diagnosis of Ph + ALL in first or subsequent 
clinical remission. 
5.1.3 Patients with CML in chronic or accelerated phase. 
5.1.4 Patients with high risk AML (Monosomy 7, secondary AML, 5q-) in 
first clinical remission. 
5.1.5 Patients with JCML or a myelodysplastic syndrome who have not 
transformed to a frank AML. 
5.1.6 Patients who have active leukemia treated as per the MISMUD 
protocol. 
5.2 Exclusion Criteria 
5.2.1 Exclusion criteria for mismatched or unrelated donor BMT will be as 
detailed in the MISMUD protocol, except patients with active 
leukemia at the time of BMT will be eligible for ETNA. 
5.2.2 Exclusion criteria at time of administration CTLs. 
5.2.2. 1 GVHD of Grade II or greater. 
5. 2. 2. 2 Patients with severe renal disease (i.e., creatinine clearance 
less than half normal for age). 
5. 2. 2. 3 Patients with severe hepatic disease (bilirubin greater than 
twice normal, or SGPT greater than 3 x normal). 
5. 2. 2. 4 Patients with a severe intercurrent infection. 
5. 2. 2. 5 Life expectancy <6 weeks. 
5. 2. 2. 6 Patients must have normal nutritional status (weight > 10th 
percentile for age, serum albumin >3 gm/dl) and 
Performance Status (ECOG) of 0-2. 
Recombinant DNA Research, Volume 17 
